Caldera says third study of PSA-test alternative shows high ability to spot Prostate cancer

Caldera says third study of PSA-test alternative shows high ability to spot Prostate cancer
Jonathan Underhill
By Jonathan Underhill Sept. 15 (BusinessDesk) - Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, says its third clinical test has shown a strong ability to identify prostate cancer and screen out those who test negative. The company is working on a replacement for the widely used PSA blood test with a simple “pee in a pot” test, using RNA biomarkers. In 2012, the US Preventive Services Task Force recommended against mass PSA screening because it t...